[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556993":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":37,"centralContacts":11,"locations":41,"responsibleParty":102,"collaborators":11,"id":104,"slug":105,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":11,"eligibilityCriteria":110,"healthyVolunteers":106,"sex":111,"minAge":112,"maxAge":11,"enrollmentInfo":113,"targetDuration":11,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":11,"overallStatus":122,"whyStopped":11,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"ONO-7475+GnP","EXPERIMENTAL",null,[13,14,15],"Drug: ONO-7475","Drug: Nab-paclitaxel","Drug: Gemcitabine",{"label":17,"type":10,"description":11,"interventionNames":18},"ONO-7475＋ONO-4538＋GnP",[13,19,14,15],"Drug: ONO-4538",[21,26,31,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","ONO-7475","Specified dose on specified days",[9,17],{"type":22,"name":27,"description":24,"armGroupLabels":28,"otherNames":29},"ONO-4538",[17],[30],"Nivolumab",{"type":22,"name":32,"description":24,"armGroupLabels":33,"otherNames":11},"Nab-paclitaxel",[9,17],{"type":22,"name":35,"description":24,"armGroupLabels":36,"otherNames":11},"Gemcitabine",[9,17],[38],{"name":39,"affiliation":5,"role":40},"Project Leader","STUDY_DIRECTOR",[42,54,58,67,76,84,93,97,99],{"facility":43,"status":11,"city":44,"state":45,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":11},"Aichi Cancer Center","Nagoya","Aichi-ken","Japan","JP",{"type":49,"coordinates":50},"Point",[51,52],136.90641,35.18147,{"lat":52,"lon":51},{"facility":55,"status":11,"city":56,"state":57,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"National Cancer Center Hospital East","Kashiwa-shi","Chiba",{"facility":59,"status":11,"city":60,"state":61,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":62,"geoPoint":66,"contacts":11},"Kanazawa University Hospital","Kanazawa","Ishikawa-ken",{"type":49,"coordinates":63},[64,65],136.61667,36.6,{"lat":65,"lon":64},{"facility":68,"status":11,"city":69,"state":70,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":71,"geoPoint":75,"contacts":11},"Kanagawa Cancer Center","Yokohama","Kanagawa",{"type":49,"coordinates":72},[73,74],139.65,35.43333,{"lat":74,"lon":73},{"facility":77,"status":11,"city":78,"state":78,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":79,"geoPoint":83,"contacts":11},"Osaka International Cancer Institute","Osaka",{"type":49,"coordinates":80},[81,82],135.50107,34.69379,{"lat":82,"lon":81},{"facility":85,"status":11,"city":86,"state":87,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":88,"geoPoint":92,"contacts":11},"Seirei Hamamatsu General Hospital","Hamamatsu","Shizuoka",{"type":49,"coordinates":89},[90,91],137.73333,34.7,{"lat":91,"lon":90},{"facility":94,"status":11,"city":95,"state":96,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Juntendo University Hpspital","Bunkyo-ku","Tokyo",{"facility":98,"status":11,"city":95,"state":96,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"The University of Tokyo Hospital",{"facility":100,"status":11,"city":101,"state":96,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"The Cancer Institute Hospital Of JFCR","Koto-Ku",{"type":103,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100556993","phase-1-a-phasestudy-of-ono-7475-in-combination-with-ono-4538-and-gemcitabine-plus-nab-paclitaxel-gnp-the-standard-of-care-and-ono-7475-in-combination-with-gnp-in-patients-with-pancreatic-cancer-100556993",false,"NCT06532331","A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer","A PhaseⅠStudy to Examine Tolerability and Safety of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and Safety of ONO-7475 in Combination With GnP in Patients With Metastatic Pancreatic Cancer as First-line Treatment","Inclusion Criteria:\n\n1. Patient with metastatic pancreatic cancer\n2. Patients have an ECOG performance status of 0 to 1\n3. Patients with a life expectancy of at least 6 months\n\nExclusion Criteria:\n\n1. Patients are unable to swallow oral medications\n2. Patients with severe complication","ALL","18 Years",{"count":114,"type":115},87,"ESTIMATED","INTERVENTIONAL",[118],"PHASE1","This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment",[121],"Metastatic Pancreatic Cancer","ACTIVE_NOT_RECRUITING","2025-04-15",{"date":125,"type":126},"2025-04-18","ACTUAL",{"date":128,"type":126},"2023-12-06",{"date":130,"type":115},"2028-03-31",{"name":5,"class":6},9]